EVH240816C35000
- 0.24
- +0.19+380.00%
Evolent Health Newsroom
Evolent Health Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Truist Raises Evolent Health to Buy, Cites Rate Increases
Evolent Health Up Nearly 27%, on Pace for Largest Percent Increase Since March 2020 -- Data Talk
Evolent Health | 10-Q: Q2 2024 Earnings Report
Earnings Call: Evolent Health Reports Revenue Growth and Strategic Acquisitions
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Evolent Health (EVH) Reports Q2 Earnings: What Key Metrics Have to Say
Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday
Sector Update: Health Care
Why Is Evolent Health, Inc. (EVH) the Best Among Engaged Capital's Current Top Holdings?
RBC Capital Keeps Their Buy Rating on Evolent Health (EVH)
Evolent Health Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results. Also, Truist Securities Upgraded the Stock From Hold to Buy and Raised Its Price Target From $28 to $33.
Express News | Evolent Health Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results. Also, Truist Securities Upgraded the Stock From Hold to Buy and Raised Its Price Target From $28 to $33
Evolent Health (EVH): A Buy Rating With Robust Growth and Strategic Initiatives
Evolent Health Q2 Adjusted Earnings, Revenue Climb; Lifts Lower End of FY Revenue Guidance
Evolent Health Is Maintained at Market Outperform by JMP Securities
Evolent Health Price Target Cut to $31.00/Share From $34.00 by JMP Securities
Express News | Evolent Health Inc : Truist Securities Raises Target Price to $33 From $28
Express News | Evolent Health Inc : Truist Securities Raises to Buy From Hold
Express News | Truist Securities Upgrades Evolent Health to Buy, Raises Price Target to $33